Home / Peptide Monographs / Cartalax

Cartalax: what the human research actually shows

Why I looked into this

Cartalax comes up in the same corners of the internet that sell Pinealon and Epitalon, always with the same bioregulator framing and always pitched for cartilage or joint regeneration. The language on vendor sites typically describes it as if there is a clinical record behind the joint claims. There is not one I can read in English.

I wanted to know what the actual published base looked like, because readers who live with joint pain are understandably curious about anything that sounds like a biological fix. The answer is roughly what it was for Pinealon: a preclinical rationale from one research program, no Western human trial, and a supplement-marketing apparatus that frames extrapolation as evidence.

What Cartalax actually is

Cartalax is a synthetic short peptide that came out of the Khavinson bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. The sequence typically reported for the AED family is Ala-Glu-Asp, a three-amino-acid fragment intended to act as a tissue-specific signaling peptide. The lab’s broader theory is that very short peptides can carry targeted regulatory information to specific tissues, which is the framing Cartalax is marketed under for cartilage.

In Russia, Cartalax is sold as a supplement-category product alongside other tissue-targeted bioregulators from the same lab. It has never been submitted for FDA review, has no US clinical trial registration, and does not appear in the Western pharmacopoeia. The only reason US readers encounter it is that research-chemical suppliers offer it under the same umbrella as Epitalon and Pinealon.

What the human research shows

Known safety signals in humans

There is no published human safety dataset for Cartalax I could locate. No Phase 1 tolerability study, no pharmacokinetic paper in humans, no independent pharmacovigilance file. Russian supplement marketing generally describes the product as well tolerated, but that claim is not backed by the kind of formal surveillance the word would imply in a Western regulatory context.

Long-term safety, interactions with common medications, reproductive effects, and any effect in young healthy adults are all unknown in the published record. Post-market adverse event reports are near-zero, which is the expected pattern for a product sold as a supplement in one country with no Western regulatory surveillance. Absence of reports is not evidence of safety.

FDA and legal status in the US

Cartalax sits entirely outside the US regulated pipeline. It is not on the 503A bulk drug substances list, it is not part of the July 2026 PCAC review, and there is no registered Western clinical trial that would move it toward consideration. The regulatory status is effectively unchanged from what it was a decade ago: a Russian supplement-category product with no US pathway.

That matters because there is no institutional check on label accuracy, identity, or purity in the US market. Whatever regulatory oversight exists happens in Russia, under a supplement framework, on a product made for a different consumer market. Import does not transfer that framework.

How to evaluate a source: the safety framework

Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.

The wrinkle for Cartalax specifically

The specific source-safety problem with Cartalax is the same shape as with Pinealon and compounded by the joint-pain use case. What gets sold as “Cartalax” in the US research-chemical market is almost never the Russian retail supplement product. It is synthesized material with no US pharmacopoeia monograph, no independent identity-testing standard, and no enforcement of what the label actually contains. A short tripeptide is straightforward to substitute with a cheaper or unrelated sequence.

The extra wrinkle here is that joint pain drives real desperation. A reader with chronic osteoarthritis who has tried the conventional options is a different audience than a biohacker experimenting on themselves out of curiosity. The identity-verification gap matters more when the decision is being made under pain and hope rather than curiosity.

Cost reality

Expect a wide price range for material labeled “Cartalax” from research-use-only suppliers, generally in the inexpensive short-peptide tier. A licensed 503A compounding pharmacy would almost certainly decline to compound it, because the compound is not on the bulk drug substances list and has no US clinical record.

Cost is a poor quality signal here. The cheap end of the market is the most likely place to see identity substitution, and the expensive end is not paying for independent testing you can verify. What you cannot buy through the research-chemical market is a chain of custody that resembles a prescription medication.

Questions worth asking any source

• Can you provide a certificate of analysis from a third-party lab, not in-house testing, confirming the tripeptide sequence reported for Cartalax?
• Are you a licensed 503A compounding pharmacy with a verifiable US state license, or a research-chemical supplier?
• Do you require a valid prescription from a licensed clinician?
• Do you have a physical US address and a phone number I can verify by calling?
• What is your process when a batch fails identity or purity testing? Who audits it?

My honest take

Questions to ask your doctor

If you are considering Cartalax, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.

1. I have been reading about Cartalax and the Russian bioregulator program for joint and cartilage claims. Are you familiar with any of it, and do you see a clinical reason a compound like this would be worth discussing in my specific situation?
2. Given that there is no published Western human clinical trial of Cartalax for joint or cartilage endpoints, how would you weigh that absence in your clinical judgment?
3. For joint pain or suspected osteoarthritis, what FDA-approved or evidence-backed options would you want to rule in or out first (physical therapy, imaging, specific interventions)?
4. What baseline labs and imaging would you want before any novel intervention, and what would you re-check later?
5. If I developed unusual symptoms while using a novel peptide (injection-site reaction, systemic symptoms, immune reaction), what should I do and who should I contact first?
6. Is there a conservative or surgical option that addresses the outcome I am hoping a bioregulator peptide would produce, with better evidence behind it?

What to do next

Sources

• Khavinson VKh et al. Short peptide bioregulator review and preclinical series on tissue-specific peptides. Bulletin of Experimental Biology and Medicine and affiliated Russian journals, multiple years. Representative PubMed index: PubMed search.
• Linkova NS et al. In-vitro and preclinical work on short peptides applied to connective-tissue and chondrocyte models, Russian-affiliated journals.
• Khavinson VKh. “Peptides and ageing.” Neuroendocrinology Letters. 2002;23 Suppl 3:11-144. PMID 12374906. Representative bioregulator-program framing paper.
• ClinicalTrials.gov and WHO International Clinical Trials Registry Platform searches for “Cartalax” and the AED tripeptide sequence, conducted April 2026. No registered or completed human clinical trial returned.
• FDA 503A bulk drug substances list, current as of April 2026. Cartalax not listed. FDA 503A bulks list.

I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.

Related monographs